Functional proteomics and molecular pharmacology of pediatric and young-onset cancers
To answer these questions, we are developing functional genomics and mass spectrometry proteomics approaches to decipher the mechanisms of genomic plasticity and adaptive signaling. Using protein engineering techniques, we rationally design and develop precisely targeted cancer therapeutic agents.
We leverage proteomics to develop improved biologic therapies, computational modeling to define oncogenic mechanisms, and innovative mouse models to determine biological functions and guide clinical trials of improved treatments, particularly for children and young adults with refractory cancers.
We are a group of physicians and scientists in the Molecular Pharmacology Program at the Sloan Kettering Institute and Department of Pediatrics and the Tow Center for Developmental Oncology at the Memorial Sloan-Kettering Cancer Center. We study the biology of cancers that affect children and young adults ranging from embryonal tumors in infants, leukemias and brain tumors in children, and sarcomas in young adults. Scientists in our group use inter-disciplinary experimental tools as they work to understand the fundamental causes of cancer and to develop definitive therapies for their control.
We are interested in understanding the principles of disorganization of genomes and proteomes of refractory leukemias and solid tumors, and determining the molecular mechanisms of response and adaptation of tumor cells to targeted therapies.
